Key Insights

Highlights

Success Rate

85% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

6.1%

6 terminated out of 99 trials

Success Rate

85.0%

-1.6% vs benchmark

Late-Stage Pipeline

8%

8 trials in Phase 3/4

Results Transparency

24%

8 of 34 completed with results

Key Signals

8 with results85% success

Data Visualizations

Phase Distribution

49Total
Not Applicable (32)
Early P 1 (1)
P 1 (3)
P 2 (5)
P 3 (6)
P 4 (2)

Trial Status

Completed34
Unknown27
Recruiting15
Not Yet Recruiting11
Terminated6
Withdrawn3

Trial Success Rate

85.0%

Benchmark: 86.6%

Based on 34 completed trials

Clinical Trials (99)

Showing 20 of 20 trials
NCT04902807Completed

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

NCT07797998Not Yet RecruitingPrimary

Association of Diet and IBD

NCT07380022Not ApplicableCompletedPrimary

Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases.

NCT04827368CompletedPrimary

Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease

NCT07782203Not ApplicableRecruiting

Establishment of a Biological Collection to Develop Translational Preclinical Models for the Study of Tumors and Diseases of the Gastrointestinal Tract

NCT07224113RecruitingPrimary

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

NCT07433946Not ApplicableRecruiting

Partial Enteral Nutrition to Prevent Weight Loss and Sarcopenia in IBD Patients at Nutritional Risk - SIMBA

NCT03759288Phase 2Terminated

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03616821Phase 2Terminated

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06844318RecruitingPrimary

Impact of IBD Activity on Frailty in Patients Over 60 Years

NCT04225819Not ApplicableSuspendedPrimary

Adjunctive Treatment With Vitamin D3 in Patients With Active IBD

NCT05698745Recruiting

Immunological Characteristics of Preclinical IBD

NCT07271264Not ApplicableRecruitingPrimary

A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endoscopy

NCT03961815Phase 3Terminated

Open-label Extension Study of Brazikumab in Crohn's Disease

NCT07300553Phase 2RecruitingPrimary

Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

NCT06146816Not ApplicableRecruitingPrimary

The Assessment of Infrared Treatment for Crohn's Disease

NCT07385807Not Yet Recruiting

Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy Outcomes With Patient With Inflammatory Bowel Disease

NCT07392606Not Yet RecruitingPrimary

Validation of PET Questionnaire for Experience and Sustainability in Telemedicine. PET(Patient Experience in Telehealth)

NCT07377188RecruitingPrimary

Pregnancy and Inflammatory Bowel Disease

NCT06381518Not ApplicableCompletedPrimary

Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease

Scroll to load more

Research Network

Activity Timeline